Traditional therapies: Glucocorticoids, azathioprine, methotrexate, hydroxyurea

Clinical and Experimental Dermatology

Volumn 27, Issue 7, 2002, Pages 546-554

  Belgi, G ^a   Friedmann, P S ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; GLUCOCORTICOID; HYDROXYUREA; METHOTREXATE;

ACUTE KIDNEY FAILURE; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ECZEMA; ERYTHEMA; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY; IMMUNE RESPONSE; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEG ULCER; LEUKEMIA; LEUKOCYTOCLASTIC VASCULITIS; LEUKOCYTOSIS; LEUKOPENIA; LUNG TOXICITY; MEGALOBLASTIC ANEMIA; MOOD DISORDER; MYALGIA; NAIL DISEASE; NAUSEA; NECROSIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PEMPHIGOID; PEMPHIGUS; POIKILODERMA; PRIORITY JOURNAL; PSORIASIS; RASH; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN DISEASE; SKIN INFLAMMATION; SMALL CELL CARCINOMA; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VERTIGO; VOMITING;

AZATHIOPRINE; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; SKIN DISEASES;

EID: 0036454607     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2002.01146.x     Document Type: Review

References (87)

1. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Mol Endocrinol 2002; 28: 69-78.
2. Beato M, Klug J. Steroid hormone receptors: An update. Hum Reprod Update 2000; 6: 225-36.
3. Beato M, Chavez S, Truss M. Transcriptional regulation by steroid hormones. Steroids 1996; 61: 240-51.
4. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 2002; 135: 511-9.
5. Croxtall JD, Flower RJ. Lipocortin 1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc Natl Acad Sci USA 1992; 89: 3571-5.
6. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: Antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002; 71: 9-15.
7. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000; 130: 289-98.
8. Taylor AD, Philip JG, John CD et al. Annexin 1 (lipocortin 1) mediates the glucocorticoid inhibition of cyclic adenosine 3′,5′-monophosphate-stimulated prolactin secretion. Endocrinology 2000; 141: 2209-19.
9. Strausbaugh HJ, Rosen SD. A potential role for annexin 1 as a physiologic mediator of glucocorticoid-induced 1- selectin shedding from myeloid cells. J Immunol 2001; 166: 6294-300.
10. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41: 761-7.
11. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia, a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983; 16: 359-63.
12. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53: 1051-6.
13. Page AR. Inhibition of lymphocyte response to inflammation with anti metabolites. Am J Pharm 1964; 45: 1029-39.
14. Hurd ER, Ziff M. Studies on the anti-inflammatory action of 6-mercaptopurine. J Exp Med 1968; 1068: 785-800.
15. Hersh EM, Wong VJ, Freireich EJ. Inhibition of the local inflammatory response in man by antimetabolites. Blood 1966; 27: 38-48.
16. Homo-Delarche F, Bach JF, Dardenne M. In vitro inhibition of prostaglandin production by azathioprine and 6-mercaptopurine. Prostaglandins 1988; 35: 479-91.
17. Levy J, Barnett EV, MacDonald NS, Klinenberg JR, Pearson CM. The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest 1972; 51: 2233-8.
18. Dimitriu A, Fauci AS. Differential sensitivity of human lymphocyte subpopulations to azathioprine. Transplant Proc 1979; 11: 878-81.
19. Levin RH, Landy M, Frie E. The effects of 6-MP on immune responses in man. New Eng J Med 1964; 271: 16.
20. Campbell AC, Skinner JM, MacLennan IC et al. Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976; 24: 249-58.
21. Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. Br Med J (Clin Res Ed) 1985; 291: 706.
22. Spencer ES, Andersen HK. Viral infections in renal allograft recipients treated with long-term immunosuppression. Br Med J 1979; 2: 829-30.
23. Paterson WD, Allen BR, Beveridge GW. Norwegian scabies during immunosuppressive therapy. Br Med J 1973; 4: 211-2.
24. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995; 133: 460-2.
25. Wolverton SE. Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol 1992; 26: 661-79.
26. Jones JJ, Ashworth J. Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol 1993; 29: 795-6.
27. Compton MR, Crosby DL. Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol 1996; 132: 1254-5.
28. Blanco R, Martinez-Taboada VM, Gonzalez-Gay MA et al. Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996; 39: 1016-20.
29. Parnham AP, Dittmer I, Mathieson PW, McIver A, Dudley C. Acute allergic reactions associated with azathioprine. Lancet 1996; 348: 542-3.
30. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984; 120: 44-7.
31. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid - A 4 year follow-up. Br J Dermatol 1974; 91: 103-9.
32. Burton JL, Harman RM, Peachey RD, Warin RP. A controlled trial of azathioprine in the treatment of pemphigoid. Br J Dermatol 1978; 99: 14.
33. Leigh IM, Hawk JL. Treatment of chronic actinic dermatitis with azathioprine. Br J Dermatol 1984; 110: 691-5.
34. Younger IR, Harris DW, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol 1991; 25: 281-6.
35. Ginzler E, Sharon E, Diamond H, Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 27-34.
36. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol 1985; 121: 1323-5.
37. Ashinoff R, Werth VP, Franks AG Jr. Resistant discoid lupus erythematosus of palms and soles: Successful treatment with azathioprine. J Am Acad Dermatol 1988; 19: 961-5.
38. du VA, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J 1974; 1: 49-51.
39. Woolfson H. Acne fulminans with circulating immune complexes and leukaemoid reaction treated with steroids and azathioprine. Clin Exp Dermatol 1987; 12: 463-6.
40. Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 1978; 41: 36-51.
41. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25-50.
42. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991; 25: 306-18.
43. Hitchings GH, Burchall JJ. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv Enzymol Relat Areas Mol Biol 1965; 27: 417-68.
44. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
45. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60.
46. Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998; 16: 235-51.
47. Mitchell MS, Wade ME, DeConti RC, Bertino JR, Calabresi P. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med 1969; 70: 535-47.
48. Glynn JPea. Effects of methotrexate and melphalan on the survival of tumor and skin homografts. Nature 1963; 198: 1003-4.
49. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-9.
50. Zachariae H, Sogaard H, Heickendorff L. Methotrexate- induced liver cirrhosis. Clinical, histological and serological studies - A further 10-year follow-up. Dermatology 1996; 192: 343-6.
51. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Met-hotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988; 19: 145-56.
52. Rothe MJ, Grin-Jorgensen C, Ramsey WH, Grant-Kels JM. Monitoring patients taking methotrexate. J Am Acad Dermatol 1995; 32: 680.
53. Petrazzuoli M, Rothe MJ, Grin-Jorgensen C, Ramsey WH, Grant-Kels JM. Monitoring patients taking methotrexate for hepatotoxicity. Does the standard of care match published guidelines? J Am Acad Dermatol 1994; 31: 969-77.
54. Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 1968; 278: 869-76.
55. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-Up Study. Cancer 1994; 73: 2759-64.
56. Moller H. Reactivation of acute inflammation by methotrexate. J Invest Dermatol 1969; 52: 437-41.
57. McDonald CJ, Bertino JR. Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Arch Dermatol 1969; 100: 655-68.
58. Roenigk HH Jr, Maibach HI, Weinstein GD. Use of methotrexate in psoriasis. Arch Dermatol 1972; 105: 363-5.
59. Rees RB, Bennett JH, Maibach HI, Arnold HL. Methotrexate for psoriasis. Arch Dermatol 1967; 95: 2-11.
60. Thomsen K. Pustulosis palmaris et plantaris treated with methotrexate. Acta Derm Venereol 1971; 51: 397-400.
61. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969; 100: 70-8.
62. Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol 1972; 106: 491-7.
63. Peck SM, Osserman KE, Samuels AJ, Berger BW, Osserman RS. Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol 1971; 103: 141-7.
64. Rivitti EA, Camargo ME, Castro RM, Sampaio SA. Use of methotrexate to treat pemphigus foliaceus. Int J Dermatol 1973; 12: 119-22.
65. Capizzi RL, Bertino JR. Methotrexate therapy of Wegener's granulomatosis. Ann Intern Med 1971; 74: 74-9.
66. Mendoza CB Jr, Gerwig WH Jr, Watne AL. Dermatofibrosarcoma protuberans with metastases treated with methotrexate. Am J Surg 1970; 120: 119-21.
67. Dantzig PI. Immunosuppressive and cytotoxic drugs in dermatology. Arch Dermatol 1974; 110: 393-406.
68. Yarbro JW, Kennedy BJ, Barnum CP. Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci USA 1965; 53: 1033-5.
69. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1-10.
70. Yarbro JW. Hydroxyurea in the treatment of refractory psoriasis. Lancet 1969; 2: 846-7.
71. Yarbro JW, Leavell UW. Hydroxyurea, a new agent for the management of refractory psoriasis. J Ky Med Assoc 1969; 67: 899-901.
72. Rosten M. Hydroxyurea, a new antimetabolite in the treatment of psoriasis. Br J Dermatol 1971; 85: 177-81.
73. Hunter GA, Simmons IJ, Thomas BM. A clinical trial of hydroxyurea for psoriasis. Australas J Dermatol 1972; 13: 93-9.
74. Moschella SL, Greenwald MA. Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch Dermatol 1973; 107: 363-8.
75. Layton AM, Sheehan-Dare RA, Goodfield MJ, Cotterill JA. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol 1989; 121: 647-53.
76. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: Its role in recalcitrant psoriasis. Int J Dermatol 2001; 40: 530-4.
77. Leavell UW Jr, Mersack IP, Smith C. Survey of the treatment of psoriasis with hydroxyurea. Arch Dermatol 1973; 107: 467.
78. Stein KM, Shelley WB, Weinberg RA. Hydroxyurea in the treatment of pustular psoriasis. Br J Dermatol 1971; 85: 81-5.
79. Lindgren S, Groth O. Generalized pustular psoriasis. A report on thirteen patients. Acta Derm Venereol 1976; 56: 139-47.
80. Zackheim HS, Karasek MA, Cox AJ Jr. Topical hydroxyurea and psoriasis. J Invest Dermatol 1972; 58: 24-7.
81. McDonald CJ. The uses of systemic chemotherapeutic agents in psoriasis. Pharmacol Ther 1981; 14: 1-24.
82. Dahl MG, Comaish JS. Long-term effects of hydroxyurea in psoriasis. Br Med J 1972; 4: 585-7.
83. Parrillo JE, Fauci AS, Wolff SM. The hypereosinophilic syndrome: Dramatic response to therapeutic intervention. Trans Assoc Am Physicians 1977; 90: 135-44.
84. Friedhoff FW, Atamer MA, Thelmo WL. Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. Chemotherapy 1978; 24: 321-6.
85. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986; 72: 317-21.
86. Young HS, Kirby B, Stewart EJ. Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. Clin Exp Dermatol 2001; 26: 664-7.
87. Donovan PB, Kaplan ME, Goldberg JD et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 1984; 17: 329-34.